Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 17/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.53 |
| ▸ | CYP11A1 | P05108 | 1/20 | 0.53 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.53 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9017823 | 0.85 | CYP19A1 (0.71) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 | |
| SCHEMBL9634038 | 0.85 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 | |
| SCHEMBL11841553 | 0.84 | CYP19A1 (0.71) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 | |
| SCHEMBL11840135 | 0.84 | CYP19A1 (0.71) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 | |
| SCHEMBL16509358 | 0.83 | CYP19A1 (0.75) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 | |
| SCHEMBL20135247 | 0.81 | CYP19A1 (0.66) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 | |
| SCHEMBL20135057 | 0.73 | CYP19A1 (0.71) | CYP19A1TSHRNPSR1 | |
| SCHEMBL14466635 | 0.71 | CYP19A1 (0.52) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 | |
| SCHEMBL20135419 | 0.69 | CYP19A1 (0.53) | CYP19A1 | |
| Rogletimide SCHEMBL4281 | 0.69 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107922347-B | Novel imide derivatives and their use as pharmaceuticals | 田边三菱制药株式会社 | 2022-06-28 | — | — | CN | disclosed |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-09-10 | — | — | US | disclosed |
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
| EP-3321256-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MMP9, MMP10, MMP1 | CYP19A1 2754/4885CYP3A4 1096/4885CYP17A1 1727/4885 |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MMP9, MMP2, MMP1 | CYP19A1 2331/4885CYP3A4 811/4885CYP17A1 1713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.